The In Vivo CRISPR Revolution: Medicine's Greatest Systemic Shift

The transition from ex vivo to in vivo gene editing marks a paradigm shift where CRISPR therapies are administered directly inside patients, democratizing access to genetic medicine and reducing global healthcare costs. This breakthrough, catalyzed by the landmark 2025 treatment of infant K.J. Muldoon, is rapidly expanding into broader pathologies, cancer immunotherapies, and AI-driven discovery.